Rapport Therapeutics, Inc. RAPP
Set alert
25.05 USD +0.84 +3.47%
At close · Oct 30
25.74 +0.69 +2.75%
After hours · Oct 30, 7:59 PM ET
23.86 Day range 25.43
22.50 52-week range 52.50
- YTD
- -17.44%
- 1 year
- -6.81%
- Open
- 23.94
- Prev close
- 24.21
- Mkt cap
- 1.20B
- Vol
- 926.56K
- Avg vol
- 686.27K
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.86
- High
- 25.43
- Forward P/E
- -4.92
- Beta
- 1.22
- Short ratio
- 6.70
- Inst. own
- 109.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 37.16
- 200-d avg
- 35.66
- 1y target
- 68.29
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.75; estimate -0.87; surprise 13.79%
- Nov 6, 2025Earnings: -0.71; estimate -0.77; surprise 7.79%
- Mar 10, 2026Earnings: -0.72; estimate -0.65; surprise -10.77%
- May 7, 2026Earnings: -0.42; estimate -0.56; surprise 25%
- Aug 5, 2026Earnings: -1.19; estimate -0.96311; surprise -23.56%
- Oct 15, 2026Rating: UBS · — → Buy
- Oct 20, 2026Rating: BTIG · Buy → Buy
- Oct 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 21, 2026Rating: Guggenheim · Buy → Buy
- Oct 21, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 21, 2026Rating: Jones Trading · Buy → Buy
Signals (36)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| RSI: Overbought | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 26, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
Key statistics
- Market cap
- 1.20B
- Enterprise value
- 735.58M
- Trailing P/E
- 0.00
- Forward P/E
- -4.92
- PEG ratio
- 0.00
- Price / sales
- 60.04
- Price / book
- 2.84
- EPS (TTM)
- -3.03
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 20.00M
- Revenue growth
- 0.00%
- Free cash flow
- -56.02M
- Total cash
- 436.08M
- Total debt
- 10.11M
- Return on equity
- -39.96%
- Shares outstanding
- 47.98M
- Short % of float
- 10.07%
- 50-day average
- 37.16
- 200-day average
- 35.66
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 68.29 +172.6% upside
Now 25.05
- Target (low)
- 50.00
- Target (mean)
- 68.29
- Target (high)
- 91.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy1
- Buy15
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.22.
Financials — quick view
RAPP Revenue — quarterly 0
RAPP Net income — quarterly -56.62M
RAPP EPS — quarterly -1.19
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.20 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.96311 | -1.19 | -0.23 | -23.56% |
| May 7, 2026 | Mar 31, 2026 | -0.56 | -0.42 | +0.14 | +25.00% |
| Mar 10, 2026 | Dec 31, 2025 | -0.65 | -0.72 | -0.07 | -10.77% |
| Nov 6, 2025 | Sep 30, 2025 | -0.77 | -0.71 | +0.06 | +7.79% |
| Aug 7, 2025 | Jun 30, 2025 | -0.87 | -0.75 | +0.12 | +13.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Jones Trading | main | Buy | Buy |
| Oct 21, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 21, 2026 | Guggenheim | main | Buy | Buy |
| Oct 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 20, 2026 | BTIG | main | Buy | Buy |
| Oct 15, 2026 | UBS | init | — | Buy |
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rapportrx.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Enphase Energy Posts Downbeat Q3 Results, Joins NXP Semiconductors, Seagate And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032
- Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
- Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
- Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed
- Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
Your note
Sign in to keep a note on RAPP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREDT DAVID | Officer | Conversion of Exercise of derivative security | Feb 18, 2026 | 393,075 |
| CEESAY ABRAHAM N | Chief Executive Officer | Sale | Oct 6, 2026 | 554,703 |
| GAULT CHERYL | Chief Operating Officer | Sale | Sep 29, 2026 | 139,914 |
| HUBER REID M. | Director | Purchase | Sep 11, 2025 | 20,400 |
| IGNELZI TROY A | Chief Financial Officer | Purchase | Oct 20, 2026 | 15,500 |
| MARAGANORE JOHN M | Director | Purchase | Oct 21, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.95% | 7,172,894 | 179.54M | Jun 29, 2026 |
| Trv Gp V, LLC | 13.09% | 6,280,525 | 157.20M | Jun 29, 2026 |
| Arch Venture Management, Llc | 7.77% | 3,728,738 | 93.33M | Jun 29, 2026 |
| Capital International Investors | 6.09% | 2,921,958 | 73.14M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.07% | 2,910,449 | 72.85M | Jun 29, 2026 |
| Blackrock Inc. | 5.63% | 2,699,786 | 67.58M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 6.51% | 3,121,012 | 78.12M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.70% | 2,257,056 | 56.49M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.06% | 986,730 | 24.70M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.65% | 793,826 | 19.87M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.44% | 692,495 | 17.33M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.24% | 594,106 | 14.87M | Aug 30, 2026 |